Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on Long-Term Safety and Effects of SAR421869 for Patients with Usher Syndrome Type 1B

Investigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying , a genetic condition that affects hearing, balance, and vision. The treatment being investigated is called , which is a special type of injection known as a . This vector is derived from a virus called the and contains a human gene known as . The purpose of the study is to evaluate the long-term safety and tolerability of this treatment in patients with Usher syndrome Type 1B.

Participants in the study will receive an injection of and will be monitored over a period of time to assess how well they tolerate the treatment and to observe any potential side effects. The study will also look at how the treatment affects the progression of the disease, particularly in terms of eye health and vision. The study is open-label, meaning that both the researchers and participants know what treatment is being administered.

The main focus of the study is to ensure that the treatment is safe for long-term use and to understand its effects on delaying the degeneration of the retina, which is a part of the eye that is crucial for vision. Participants will undergo regular assessments to monitor their eye health and any changes in their condition. The study aims to provide valuable information on the potential benefits and risks of using for treating Usher syndrome Type 1B.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after providing signed and dated written informed consent. This includes any necessary local authorizations, such as the Health Insurance Portability and Accountability Act (HIPAA).

    Eligibility requires previous enrollment in protocol TDU13600 and having received a subretinal injection of SAR421869.

  2. Step 2

    Treatment administration

    SAR421869 is administered as a suspension for injection. The specific route of administration is not detailed in the available information.

  3. Step 3

    Monitoring and assessments

    The study aims to evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B.

    Primary assessments focus on the incidence of adverse events.

    Secondary assessments include monitoring for clinically important changes in eye safety and any delay in retinal degeneration.

  4. Step 4

    Study duration

    The study is expected to continue until June 18, 2031.

Who can join the trial?

6 criteria

  • Provide signed and dated written informed consent. This means you agree to participate in the study and understand what it involves. If needed, provide assent, which is a way for younger participants to agree.
  • Have any required local authorization, such as the Health Insurance Portability and Accountability Act (HIPAA), which is a law that protects your health information.
  • Must have been enrolled in a previous study with the code TDU13600.
  • Must have received a subretinal injection of SAR421869. A subretinal injection is a procedure where a small amount of medicine is placed under the retina, which is a part of the eye.
  • Both males and females can participate.
  • Participants can be from vulnerable populations, which means groups that might need special protection or care.

Who cannot join the trial?

5 criteria

  • Patients who do not have **Usher's syndrome Type 1B** cannot participate. **Usher's syndrome** is a condition that affects hearing and vision.
  • Patients who are not within the specified age range for the study cannot participate. The age range is not specified here, but it is important for eligibility.
  • Patients who are not part of the specified clinical trial group cannot participate. This refers to a specific group of patients that the study is focusing on.
  • Patients who are not male or female cannot participate. The study includes both male and female participants.
  • Patients who are not considered part of a vulnerable population cannot participate. A **vulnerable population** includes groups that may need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

SAR421869 is a medication being studied for its long-term safety and tolerability in patients with Usher syndrome Type 1B. This trial aims to understand how well patients can handle the medication over an extended period and to observe any biological effects it may have. Usher syndrome Type 1B is a genetic condition that affects hearing and vision, and this study is focused on finding a treatment that could potentially help manage these symptoms.

What is already known about the treatment

SAR421869 – This medication is administered through an injection, specifically designed for patients with Usher syndrome Type 1B. Currently, it is under investigation in clinical trials to assess its long-term safety and tolerability. The main therapeutic indication is to address symptoms associated with Usher syndrome, a condition that affects hearing and vision. At the molecular level, SAR421869 works by targeting specific pathways involved in the disease process, although the exact mechanism is still being studied. It falls under the pharmacological classification of investigational drugs, as it is not yet approved for general medical use.

Investigated diseases

Usher Syndrome Type 1B – Usher Syndrome Type 1B is a genetic disorder characterized by hearing loss and progressive vision loss. Individuals with this condition are typically born with severe to profound hearing impairment and experience balance issues due to inner ear problems. Vision loss usually begins in childhood or adolescence and is caused by a condition called retinitis pigmentosa, which leads to the degeneration of the retina. As the disease progresses, individuals may experience night blindness and a narrowing of the field of vision. Over time, the vision impairment can become more severe, affecting daily activities. The progression of symptoms can vary among individuals, but the combination of hearing and vision loss significantly impacts communication and mobility.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-513500-34-00Protocol codeLTS13619Estimated enrolment9 patientsSponsorSanofi-Aventis Recherche & Developpement

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).